Hematology
Clinical
Anticoagulant choice in antiphospholipid syndrome–associated thrombosis
Are direct oral anticoagulants (DOACs) as efficacious and safe as vitamin K antagonists (VKAs) in treating thrombosis secondary to...
Clinical
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
Is apixaban a safe alternative to warfarin in patients with severe renal impairment?
News
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Clinical
Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE
Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?
Clinical
Tranexamic acid does not reduce risk of death in GI bleed
In patients with GI bleeding, does high-dose tranexamic acid (TXA) reduce the risk of death?
Clinical
Oakland score identifies patients with lower GI bleed at low risk for adverse events
Is the Oakland score a valid tool to assess the risk of adverse outcomes in adult patients with acute lower GI bleed (LGIB)?
Clinical
Timing of endoscopy for acute upper GI bleeding
In high-risk patients hospitalized with upper GI bleeding, is earlier endoscopy beneficial?
News
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Clinical
Autopsy findings reveal venous thromboembolism in patients with COVID-19
What pathologic features contribute to the cause of death in COVID-19?
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.